- Home
- ISDR vs AKTX Comparison
ISDR vs AKTX Comparison
Compare ISDR & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISDR
- AKTX
- Stock Information
- Founded
- ISDR 1988
- AKTX N/A
- Country
- ISDR United States
- AKTX United States
- Employees
- ISDR N/A
- AKTX N/A
- Industry
- ISDR Publishing
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ISDR Consumer Discretionary
- AKTX Health Care
- Exchange
- ISDR Nasdaq
- AKTX Nasdaq
- Market Cap
- ISDR 36.2M
- AKTX 37.4M
- IPO Year
- ISDR N/A
- AKTX N/A
- Fundamental
- Price
- ISDR $10.49
- AKTX $3.32
- Analyst Decision
- ISDR
- AKTX
- Analyst Count
- ISDR 0
- AKTX 0
- Target Price
- ISDR N/A
- AKTX N/A
- AVG Volume (30 Days)
- ISDR 11.5K
- AKTX 15.4K
- Earning Date
- ISDR 08-08-2024
- AKTX 09-27-2024
- Dividend Yield
- ISDR N/A
- AKTX N/A
- EPS Growth
- ISDR N/A
- AKTX N/A
- EPS
- ISDR N/A
- AKTX N/A
- Revenue
- ISDR $29,757,000.00
- AKTX N/A
- Revenue This Year
- ISDR N/A
- AKTX N/A
- Revenue Next Year
- ISDR N/A
- AKTX N/A
- P/E Ratio
- ISDR N/A
- AKTX N/A
- Revenue Growth
- ISDR N/A
- AKTX N/A
- 52 Week Low
- ISDR $7.61
- AKTX $1.08
- 52 Week High
- ISDR $21.00
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ISDR 55.25
- AKTX 42.60
- Support Level
- ISDR $9.45
- AKTX $3.25
- Resistance Level
- ISDR $12.48
- AKTX $3.87
- Average True Range (ATR)
- ISDR 0.76
- AKTX 0.37
- MACD
- ISDR 0.15
- AKTX -0.05
- Stochastic Oscillator
- ISDR 44.26
- AKTX 9.10
About ISDR Issuer Direct Corporation
Issuer Direct Corp is a communications and compliance company. It focuses on the needs of corporate issuers. It provides disclosure management solutions, shareholder communications tools, and cloud-based compliance technologies. Its customers include public and private companies, mutual funds, law firms, brokerage firms, investment banks, individuals, and other institutions. Its products include PR solutions, IR solutions, Compliance, and Event management software.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).